Main Article Content
Abstract
Keywords
Article Details
References
- Angsar MD (2010). Hipertensi dalam kehamilan. In S. Prawirohardjo, Ilmu Kebidanan. Jakarta, PT. Bina Pustaka Sarwono Prawirohardjo, p 530-50
- Cunningham F, et al (2010). Williams Obstetric. 23th ed. New York, McGraw-Hill Education
- Davison J, et al (2004). New Aspects in Patho-physiology of Preeclampsia. Journal of the American Society of Nephrology 15, 2440-2448
- Day MD, et al (1973). The mechanism of the a enti-hypertensive action of methyldopa in hypertensive rats. Eur J Pharmacol 21, 271-280
- Hattori Y, Yamamoto S, Matsuda N (2007). Sympa-thetic control of VEGF angiogenic signaling. Circula-tion Research 101, 642-4
- Henning M, Rubenson A (1971) Evidence that the hypotensive action of methyldopa is mediated by central actions of methylnoradrenaline. J Pharm Phar-macol 23, 407-11
- Kahlil A (2008). Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factor in pregnancies with hypertensive disorders. Plos ONE 6, 5-21
- Levine RJ, et al (2004). Circulating angiogenic factors and the risk of preeclampsia. The New England Journal Medicine 350, 672-683
- Maynard SE (2003). Excess placental soluble Fms-like tyrosine kinase 1 (sFlt-1) may contribute to endho-telial dysfunction, hypertension, and proteinuria I preeclampsia. J The Journal of Clinical Investigation 111, 649-658
- Maynard SE, et al (2003). Soluble Fms-like tyrosine kinase 1 and endothelial disfunction in the patho-genesis of preeclampsia. Department of Medicine 57, 5
- Zhang Z, et al (2012). Hypoxia-induce factor-1 alpha signaling: Regulation of vascular endothelial growth factor-dependent angiogenesis during ovarian corpus luteum development in mammals. Journal of Vete-rinary Medicine and Animal Health 4, 97-104
References
Angsar MD (2010). Hipertensi dalam kehamilan. In S. Prawirohardjo, Ilmu Kebidanan. Jakarta, PT. Bina Pustaka Sarwono Prawirohardjo, p 530-50
Cunningham F, et al (2010). Williams Obstetric. 23th ed. New York, McGraw-Hill Education
Davison J, et al (2004). New Aspects in Patho-physiology of Preeclampsia. Journal of the American Society of Nephrology 15, 2440-2448
Day MD, et al (1973). The mechanism of the a enti-hypertensive action of methyldopa in hypertensive rats. Eur J Pharmacol 21, 271-280
Hattori Y, Yamamoto S, Matsuda N (2007). Sympa-thetic control of VEGF angiogenic signaling. Circula-tion Research 101, 642-4
Henning M, Rubenson A (1971) Evidence that the hypotensive action of methyldopa is mediated by central actions of methylnoradrenaline. J Pharm Phar-macol 23, 407-11
Kahlil A (2008). Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factor in pregnancies with hypertensive disorders. Plos ONE 6, 5-21
Levine RJ, et al (2004). Circulating angiogenic factors and the risk of preeclampsia. The New England Journal Medicine 350, 672-683
Maynard SE (2003). Excess placental soluble Fms-like tyrosine kinase 1 (sFlt-1) may contribute to endho-telial dysfunction, hypertension, and proteinuria I preeclampsia. J The Journal of Clinical Investigation 111, 649-658
Maynard SE, et al (2003). Soluble Fms-like tyrosine kinase 1 and endothelial disfunction in the patho-genesis of preeclampsia. Department of Medicine 57, 5
Zhang Z, et al (2012). Hypoxia-induce factor-1 alpha signaling: Regulation of vascular endothelial growth factor-dependent angiogenesis during ovarian corpus luteum development in mammals. Journal of Vete-rinary Medicine and Animal Health 4, 97-104